Could a common diabetes drug calm erratic heartbeats?
NCT ID NCT05174052
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether dapagliflozin, a diabetes medication, can reduce the amount of time people with diabetes spend in atrial fibrillation (an irregular heart rhythm). About 28 adults with both conditions will wear a heart monitor and complete quality-of-life surveys. The goal is to see if the drug lowers AF burden and improves well-being over three months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Oklahoma Health Sciences Center
RECRUITINGOklahoma City, Oklahoma, 73104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- FitBit coaching may help amputees walk more after surgery
- A tiny neck implant could catch Stroke-Causing clots before they reach the brain
- Could a bigger balloon tame the Heart's electrical chaos?
- Can AI catch the leading cause of blindness before It's too late?
- Could a new injection tame atrial fibrillation?
- Can a new heart ablation technique work without x-rays?